David Cheng Profile
David Cheng

@Cheng15

Followers
151
Following
2K
Media
20
Statuses
180

Cancer epidemiologist. Studying precision cancer prevention and cancer health disparities. @jnci_now

The Ohio State University
Joined August 2009
Don't wanna be here? Send us removal request.
@Cheng15
David Cheng
1 year
En Cheng visited OSU and presented his research on body composition. Fascinating presentation and discussion! @EnCheng23 @OSUCCC_James
0
0
3
@ithinkwellHugh
Hugh Kearns
1 year
September 16-20 is National Postdoc appreciation week. #NPAW2024 https://t.co/pOHAT0N9QY
1
32
95
@EricTopol
Eric Topol
1 year
Tricking the animal model that it is getting excess nutrients leads to inflammation, organ damage, and shortened lifespan, reversed by anti-inflammatory Rx https://t.co/gvxgceAWWP @NatureAging @AnaOrtegaMolin1 @EfeyanLab @CNIOStopCancer @AgEInves @SaludISCIII @justsaysinmice
2
30
130
@JAMAOnc
JAMA Oncology
1 year
Most viewed in the last 7 days from @JAMAOnc: Is there an association between body composition metrics automatically extracted from imaging and prognoses in patients with advanced NSCLC receiving systemic therapy? https://t.co/hyzhQAfZtt
0
2
8
@stolaney1
Sara Tolaney
1 year
RxPONDER: outcomes by race+ ethnicity (n=3102), median f/u 8 yrs (5% NH Black, 70% NH White) Worse outcome for NH Blacks c/w NH whites NH Blacks have higher mean proliferation axis score c/w NH Whites , but BMI may also have a role @OncoAlert #ASCO24 #bcsm
0
11
22
@stolaney1
Sara Tolaney
1 year
Carolina Breast Cancer Study: assoc between MHC I +II and race. (total n=1630, 787=black; 68% HR+/HER2-) presented by Sonya Reid MHCI + II more common in black in HR+/HER2- BC (this could potentially translate into improved response to IO) @OncoAlert #bcsm #ASCO24
0
5
12
@OhioStatePIIO
Pelotonia Institute for Immuno-Oncology
1 year
Excited to hear Dr. Ephraim Ansa-Addo's presentation on modulating #TregCells for #cancer #immunotherapy during our #PIIO Research-in-Progress! His research focuses on defining the functions of various subsets of #TregCells in the #TME & how they affect cancer progression.
0
1
8
@IRPatNIH
NIH Intramural
1 year
Close out Asian American, Native Hawaiian, and Pacific Islander Heritage Month by listening to our new #SpeakingofScience episode! We break down some of the history that has shaped #AANHPI experiences and perspectives and explain why researchers like Dr. Jacqueline Vo are working
0
3
2
@OhioStateMedOnc
Ohio State Medical Oncology
1 year
Join our @OhioStateMedOnc faculty at #ASCO24 to learn about our latest research! @AshishManne @shafiarahman_ @StoverLab @CPresGeriOncMD
0
6
15
@CAPR_AACR
Cancer Prevention Research
1 year
Read the article by the recipients of the Cancer Prevention Research Award for Outstanding Journal Article, Denise Cecil et al.— COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors & Increase the Influx of Type I Tumor-infiltrating Lymphocytes. https://t.co/quyZZqjLub
@CAPR_AACR
Cancer Prevention Research
1 year
Congratulations to Denise Cecil, PhD, and colleagues, recipients of the Cancer Prevention Research Award for Outstanding Journal Article! Learn more about this award: https://t.co/WZwsFMRV6W @UWCancerVaccine #CancerPrevention
0
1
0
@MinorityHealth
Minority Health
1 year
A7: @NCIEpiTraining explains that disaggregated data can reveal variations in health disparities experienced by #AAs & #NHPIs and can help avoid making misleading conclusions about AA and NHPI health: https://t.co/OWByXOE4nY #SourceForBetterHealth (1/2)
1
1
0
@HasanovLab
Elshad Hasanov, MD, PhD
2 years
🔍 Hiring Alert: We’re seeking bioinformaticians at various levels to elevate our translational research at @HasanovLab @OhioStatePIIO Join us in navigating the complexities of data to unveil groundbreaking findings 🧬🖥️ Your RTs to spread the word are greatly appreciated 🙏
1
10
14
@OhioStatePIIO
Pelotonia Institute for Immuno-Oncology
1 year
Kudos to #PIIO, @OhioStateMedOnc faculty recruit Dr. Tim Gauntner, who rec'd a 2024 @ConquerCancerFd Young Investigator Award. W/ interests in #genitourinary #oncology, he works in the areas of #immune regulation in the #TME, steroid hormone signaling, & hormonal carcinogenesis.
@ConquerCancerFd
Conquer Cancer, the ASCO Foundation
1 year
Congratulations to this year's class of Conquer Cancer Grant and Award recipients! We can't wait to celebrate with you at #ASCO24! Full list of recipients: https://t.co/mCaRLSVLik
0
4
17
@cancer_area
Cancer Center Catchment Area
1 year
Female breast cancer incidence rate. Ohio ranked #9 in the nation
0
1
1
@JohnsHopkinsEPI
Johns Hopkins Epidemiology
1 year
.@JohnsHopkins invites applications and nominations for the position of Editor-in-Chief (EiC) of a new open access (OA), online-only, peer-reviewed epidemiology journal, AJE Open, part of the American Journal of Epidemiology.
1
4
4
@NCICancerStats
NCI Cancer Stats
1 year
The rate of new HR-/HER2- (or “triple-negative”) #BreastCancer cases is higher than average for Non-Hispanic Black women. The average rate of new cases increased across all racial and ethnic groups from 2016 to 2021. SEER*Explorer has more stats: https://t.co/ANRZCA8cR3 #BCSM
0
1
1
@JNCI_Now
JNCI
1 year
Commentary by Manz and Barnett discusses the role of “linchpin” oncologists, central to patients in cancer care referral networks such as rural and low SES communities. Read more here: https://t.co/xs9AYWexzG @ml_barnett @DanaFarber @harvardmed @HarvardChanSPH
Tweet card summary image
academic.oup.com
Medical, radiation, and surgical oncologists, like other clinicians, are practicing in increasingly complex professional networks. Expanding subspecializat
0
3
2
@VivekSubbiah
Vivek Subbiah, MD
2 years
⭐️Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies @AACR @CCR_AACR @CRC_AACR
Tweet card summary image
aacrjournals.org
AbstractBackground:. Sapanisertib (CB-228/TAK-228) is a potent, selective ATP-competitive, dual inhibitor of mTORC1/2. Metformin is thought to inhibit the mTOR pathway through upstream activation of...
0
4
7
@CCR_AACR
Clinical Cancer Research
2 years
All that is small is not a small cell carcinoma: Thoracic SMARCA4 undifferentiated tumors masquerading as SCLC. https://t.co/aMCJkTI6nQ
0
24
49
@OhioStatePIIO
Pelotonia Institute for Immuno-Oncology
2 years
🚨JOB ALERT🚨 #PIIO #ImmuneMonitoring & Discovery Platform ( https://t.co/OuGHnXMT0M) seeks a #FlowCytometry Scientist w/ at least 5-10 yrs experience w/ flow instruments (Cytek Aurora, BD FACS Melody, etc.) & proficiency in FlowJo & Omiq. For more info👇 https://t.co/WXLc3tMDiJ
0
5
9